Patrick Aisher

Chairman Kinled Holding Limited

Patrick Aisher is a prominent figure in the investment landscape, currently serving as the Director at CEBINA Bridge Capital, a specialized fund focused on investing in pharmaceutical drug development in Central and Eastern Europe. He is a serial entrepreneur with a significant background in the life sciences sector, having invested since 1997 in various biomedical technology companies, including medical devices and biopharmaceuticals.1 2

Professional Background

Investment Experience: Aisher has participated in over 40 direct investments, achieving notable exits such as:
- KB Medical sold to Globus for $40 million in 2018.
- Medina Medical acquired by Medtronic for over $150 million in 2016.
- Licensing transactions valued at $350 million.1 2
Leadership Roles: In addition to his role at CEBINA, Aisher is the Chairman of Kinled Holding Limited, which manages a portfolio of over 125 companies across various sectors, including fintech and biotech. He has also been instrumental in founding several technology funds in major cities like Boston and Zurich, managing assets totaling approximately €350 million.2 3
Focus on Innovation: Aisher emphasizes early-stage funding for biotech projects, bridging the gap between academic research and clinical application. His initiatives include financing projects through Danube Labs, which collaborates with universities and research institutions across Europe.1 2

Strategic Vision

Aisher's strategic vision includes expanding investment opportunities within the biotech sector, particularly through CEBINA Bridge Capital, which aims to fund innovative projects and support startups combating various health challenges. He is also developing a new fund focused on technologies for central nervous system diseases.2

In summary, Patrick Aisher combines entrepreneurial spirit with extensive investment expertise, particularly in the life sciences, making significant contributions to advancing biotech innovations in Europe.